Kymera Therapeutics Inc Earnings

Kymera Therapeutics Inc’s revenue fell -84.56% since last year same period to $7.39Mn in the Q4 2024. On a quarterly growth basis, Kymera Therapeutics Inc has generated 97.65% jump in its revenue since last 3-months.

Kymera Therapeutics Inc’s net profit fell -392.43% since last year same period to $-70.75Mn in the Q4 2024. On a quarterly growth basis, Kymera Therapeutics Inc has generated -13.23% fall in its net profits since last 3-months.

Kymera Therapeutics Inc’s net profit margin fell -3089.06% since last year same period to -956.88% in the Q4 2024. On a quarterly growth basis, Kymera Therapeutics Inc has generated 42.71% jump in its net profit margins since last 3-months.

Kymera Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.73 - a 7.38% jump from last quarter’s estimates.

Kymera Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.73.

Kymera Therapeutics Inc’s earning per share (EPS) fell -256% since last year same period to -0.89 in the Q4 2024. This indicates that the Kymera Therapeutics Inc has generated -256% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kymera Therapeutics Inc’s return on assets (ROA) stands at -0.21.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kymera Therapeutics Inc’s return on equity (ROE) stands at -0.36.